Biomarker

A biomarker is something measurable — a blood level, scan, physical sign, or defined characteristic — used to show what is happening in the body. Researchers often choose one because the outcome they care about takes longer or is harder to observe. The catch: moving the marker does not automatically improve that outcome.

What is a biomarker?

A biomarker is an objective measurement that indicates a biological process, disease process, or response to treatment. Blood glucose, blood pressure, hormone concentrations, and tumor size on a scan can all qualify. That is the practical biomarker meaning: a finding that gives researchers information without asking whether someone feels or functions better.

Biomarkers can diagnose disease, help select trial participants, track safety, or show that a compound reached its target. The FDA definition draws a firm boundary: a biomarker is not itself a measure of how a person feels, functions, or survives.

Is a biomarker the same as a surrogate marker?

A surrogate marker is a biomarker used in place of a direct clinical outcome, but not every biomarker earns that job. Hemoglobin A1c (HbA1c), for example, is a validated surrogate endpoint for microvascular complications in diabetes in a defined setting. Validation requires evidence that the stand-in predicts clinical benefit.

That context matters. FDA warns that even a validated surrogate can miss benefits or harms outside the pathway it measures. A lower laboratory value is a result; fewer complications is a different result. The endpoint glossary explains how trials choose between them.

Is IGF-1 a biomarker of peptide results?

IGF-1 is a biomarker of growth-hormone-axis activity, not automatic proof of muscle gain, recovery, or longer life. Sermorelin can raise growth hormone and IGF-1 in people, so a higher IGF-1 biomarker shows that the hormonal pathway responded. The outcome claim still needs its own measurements: strength, body composition, daily function, or another result people care about.

The same caution applies to GDF-11, where blood-test interpretation is part of the scientific dispute. Ask whether a test measured the intended molecule cleanly and whether that measurement predicts the claimed benefit.

How should you read a biomarker result?

Read a biomarker result as evidence for exactly what was measured, then stop before adding an unmeasured benefit. Ask whether the marker was merely associated with the outcome, whether it is a validated surrogate for this specific use, and whether the study also measured how people felt or functioned.

Target engagement is not treatment success. The guide to reading peptide evidence shows how to place the result on the right evidence rung without promoting an early signal into a clinical win.